A fragment of human growth hormone that targets fat metabolism without the growth-promoting effects of full HGH.
Molecular Weight
1817.1 Da
Half-Life
~30 minutes
Typical Dose
300–500 mcg
Cycle Length
8–12 weeks
Description
AOD-9604 is a modified fragment of human growth hormone (hGH) corresponding to amino acids 176–191 of the hGH sequence. Originally developed by Monash University in Australia as part of an anti-obesity drug program, it was designed to isolate the lipolytic (fat-burning) properties of HGH without triggering the growth-promoting, insulin-desensitizing, or carcinogenic risks associated with full HGH administration. The peptide completed Phase IIb clinical trials for obesity and received GRAS (Generally Recognized as Safe) status from the FDA for use as a food additive, making it one of the few research peptides with a formal safety assessment. Beyond fat loss, preclinical research has suggested potential applications in cartilage repair and osteoarthritis, adding to its research interest.
* Benefits based on preclinical/animal research unless otherwise noted.
Peptide Protocol Education Portal
Members-Only Access
Access advanced peptide education, protocol insights, and research-based information curated for informed users. Create a free account or log in to continue.
Please acknowledge the disclaimer above to continue.